Sophia DeLuca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sophia DeLuca has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Nenad Bursac
Duke University
10 shared publications - Tianyu Wu
Department of Biomedical Engineering, Duke University, Durham, NC
5 shared publications - Nicholas Strash
Department of Biomedical Engineering Duke University Durham NC 27708 USA
4 shared publications - Andrew P. Landstrom
Department of Pediatrics, Division of Cardiology, Children’s Hospital of Philadelphia, Philadelphia & Perelman School of Medicine, University of Pennsylvania, Philadelphia (B.B., A.P.L.).
3 shared publications Craig Henriquez
Department of Biomedical Engineering, Duke University, Durham, NC, USA
3 shared publications- Geovanni L. Janer Carattini
Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305
3 shared publications
Latest Publications
- Open Access
- 20 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (12) , eady4551
Regulation of sodium/calcium homeostasis by BacNa v gene therapy rescues cardiac dysfunction in chronic heart failure
Despite continued progress, therapies to augment contractile function and prevent arrhythmias in patients with heart failure remain limited. Here, we present a two-pronged gene therapy approach that simultaneously augments peak Na + current and Ca 2+ transient amplitude in cardiomyocytes (CMs) to alleviate heart failure pathogenesis. Using in vitro engineered neonatal rat heart tissues, ex vivo adult mouse CMs, and in silico rabbit CMs, we show that expression of prokaryotic Na + channels (BacNa v ) dose-dependently enhances Ca 2+ transients and contractility of CMs by modulating Na + /Ca 2+ exchanger activity and increasing sarcoplasmic reticulum Ca 2+ stores. In mice, adeno-associated virus 9 (AAV9)–mediated BacNa v therapy rescues contractile deficit, prevents arrhythmias, and improves transcriptomic dysregulation in a pressure-overload induced model of chronic heart failure. We further establish the safety of long-term systemic delivery of AAV9-BacNa v in mice. Collectively, these studies support the translational promise of BacNa v gene delivery as an effective therapy for electrical and contractile dysfunction in heart failure.
- 20 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (12) , eady4551
Open AccessRegulation of sodium/calcium homeostasis by BacNa v gene therapy rescues cardiac dysfunction in chronic heart failure
Despite continued progress, therapies to augment contractile function and prevent arrhythmias in patients with heart failure remain limited. Here, we present a two-pronged gene therapy approach that simultaneously augments peak Na + current and Ca 2+ transient amplitude in cardiomyocytes (CMs) to alleviate heart failure pathogenesis. Using in vitro engineered neonatal rat heart tissues, ex vivo adult mouse CMs, and in silico rabbit CMs, we show that expression of prokaryotic Na + channels (BacNa v ) dose-dependently enhances Ca 2+ transients and contractility of CMs by modulating Na + /Ca 2+ exchanger activity and increasing sarcoplasmic reticulum Ca 2+ stores. In mice, adeno-associated virus 9 (AAV9)–mediated BacNa v therapy rescues contractile deficit, prevents arrhythmias, and improves transcriptomic dysregulation in a pressure-overload induced model of chronic heart failure. We further establish the safety of long-term systemic delivery of AAV9-BacNa v in mice. Collectively, these studies support the translational promise of BacNa v gene delivery as an effective therapy for electrical and contractile dysfunction in heart failure.
- Open Access
- 9 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
Ddx61-enriched condensates refine heart regeneration programs
Gene regulatory mechanisms that underlie tissue regeneration have been largely studied at the level of transcription. Here, proximity labeling methods identify increased presence of the RNA helicase and P-body marker Ddx61 in adult zebrafish cardiomyocytes induced to divide by injury or mitogens. Ddx61 molecules form complex condensates in cardiomyocytes during cardiogenic settings in zebrafish, developing mice, and cultured human cells. ddx61 mutations disrupt cardiomyocyte proliferation and heart regeneration indices in adult zebrafish, and DDX6 knockdown reduces proliferation of cultured human cardiomyocytes. During heart regeneration, Ddx61 associates with and is required to restrain expression of mRNA encoding Chordin, a secreted BMP inhibitor that impedes regeneration if present at high levels. Our experiments indicate that mRNA sorting by context-dependent condensates can impact tissue regenerative capacity.
- 9 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
Open AccessDdx61-enriched condensates refine heart regeneration programs
Gene regulatory mechanisms that underlie tissue regeneration have been largely studied at the level of transcription. Here, proximity labeling methods identify increased presence of the RNA helicase and P-body marker Ddx61 in adult zebrafish cardiomyocytes induced to divide by injury or mitogens. Ddx61 molecules form complex condensates in cardiomyocytes during cardiogenic settings in zebrafish, developing mice, and cultured human cells. ddx61 mutations disrupt cardiomyocyte proliferation and heart regeneration indices in adult zebrafish, and DDX6 knockdown reduces proliferation of cultured human cardiomyocytes. During heart regeneration, Ddx61 associates with and is required to restrain expression of mRNA encoding Chordin, a secreted BMP inhibitor that impedes regeneration if present at high levels. Our experiments indicate that mRNA sorting by context-dependent condensates can impact tissue regenerative capacity.
- 24 March 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (12) , e2404695
Human Myobundle Platform for Studying the Role of Notch Signaling in Satellite Cell Phenotype and Function
Notch signaling plays a pivotal role in regulating satellite cell (SC) behavior during skeletal muscle development, homeostasis, and repair. While well‐characterized in mouse models, the impact of Notch signaling in human muscle tissues remains largely underexplored. Here, a 3D tissue‐engineered model of human skeletal muscle (“myobundles”) is utilized as an in vitro platform for temporal control and studies of Notch singaling. Myofiber‐specific overexpression of the Notch ligand, DLL1, early in myobundle differentiation increases the abundance of 3D SCs and shifts their phenotype to a more quiescent‐like state, along with decreasing muscle mass and function. In contrast, myofiber‐specific DLL1 overexpression after one week of myobundle differentiation does not affect 3D SC abundance or muscle function, but increases transcriptomic markers of SC quiescence, confirming the temporal dependence of SC activation and self‐renewal on Notch signaling activity. Finally, for the first time these studies show that even after a transient, myofiber‐specific upregulation of Notch signaling in myobundles, 3D SCs expanded from these tissues can re‐form functional “secondary” myobundles containing an amplified SC pool. Future studies in the described human myobundle platform are expected to aid the development of novel Notch‐targeted therapies for muscular dystrophies and aging.
- 24 March 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (12) , e2404695
Human Myobundle Platform for Studying the Role of Notch Signaling in Satellite Cell Phenotype and Function
Notch signaling plays a pivotal role in regulating satellite cell (SC) behavior during skeletal muscle development, homeostasis, and repair. While well‐characterized in mouse models, the impact of Notch signaling in human muscle tissues remains largely underexplored. Here, a 3D tissue‐engineered model of human skeletal muscle (“myobundles”) is utilized as an in vitro platform for temporal control and studies of Notch singaling. Myofiber‐specific overexpression of the Notch ligand, DLL1, early in myobundle differentiation increases the abundance of 3D SCs and shifts their phenotype to a more quiescent‐like state, along with decreasing muscle mass and function. In contrast, myofiber‐specific DLL1 overexpression after one week of myobundle differentiation does not affect 3D SC abundance or muscle function, but increases transcriptomic markers of SC quiescence, confirming the temporal dependence of SC activation and self‐renewal on Notch signaling activity. Finally, for the first time these studies show that even after a transient, myofiber‐specific upregulation of Notch signaling in myobundles, 3D SCs expanded from these tissues can re‐form functional “secondary” myobundles containing an amplified SC pool. Future studies in the described human myobundle platform are expected to aid the development of novel Notch‐targeted therapies for muscular dystrophies and aging.
- 7 November 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (1)
Engineered Cardiac Tissues as a Platform for CRISPR‐Based Mitogen Discovery
Improved understanding of cardiomyocyte (CM) cell cycle regulation may allow researchers to stimulate pro‐regenerative effects in injured hearts or promote maturation of human stem cell‐derived CMs. Gene therapies, in particular, hold promise to induce controlled proliferation of endogenous or transplanted CMs via transient activation of mitogenic processes. Methods to identify and characterize candidate cardiac mitogens in vitro can accelerate translational efforts and contribute to the understanding of the complex regulatory landscape of CM proliferation and postnatal maturation. In this study, A CRISPR knockout‐based screening strategy using in vitro neonatal rat ventricular myocyte (NRVM) monolayers is established, followed by candidate mitogen validation in mature 3‐D engineered cardiac tissues (ECTs). This screen identified knockout of the purine metabolism enzyme adenosine deaminase (ADA‐KO) as an effective pro‐mitogenic stimulus. RNA‐sequencing of ECTs further reveals increased pentose phosphate pathway (PPP) activity as the primary driver of ADA‐KO‐induced CM cycling. Inhibition of the pathway's rate limiting enzyme, glucose‐6‐phosphate dehydrogenase (G6PD), prevented ADA‐KO induced CM cycling, while increasing PPP activity via G6PD overexpression increased CM cycling. Together, this study demonstrates the development and application of a genetic/tissue engineering platform for in vitro discovery and validation of new candidate mitogens affecting regenerative or maturation states of cardiomyocytes.
- 7 November 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (1)
Engineered Cardiac Tissues as a Platform for CRISPR‐Based Mitogen Discovery
Improved understanding of cardiomyocyte (CM) cell cycle regulation may allow researchers to stimulate pro‐regenerative effects in injured hearts or promote maturation of human stem cell‐derived CMs. Gene therapies, in particular, hold promise to induce controlled proliferation of endogenous or transplanted CMs via transient activation of mitogenic processes. Methods to identify and characterize candidate cardiac mitogens in vitro can accelerate translational efforts and contribute to the understanding of the complex regulatory landscape of CM proliferation and postnatal maturation. In this study, A CRISPR knockout‐based screening strategy using in vitro neonatal rat ventricular myocyte (NRVM) monolayers is established, followed by candidate mitogen validation in mature 3‐D engineered cardiac tissues (ECTs). This screen identified knockout of the purine metabolism enzyme adenosine deaminase (ADA‐KO) as an effective pro‐mitogenic stimulus. RNA‐sequencing of ECTs further reveals increased pentose phosphate pathway (PPP) activity as the primary driver of ADA‐KO‐induced CM cycling. Inhibition of the pathway's rate limiting enzyme, glucose‐6‐phosphate dehydrogenase (G6PD), prevented ADA‐KO induced CM cycling, while increasing PPP activity via G6PD overexpression increased CM cycling. Together, this study demonstrates the development and application of a genetic/tissue engineering platform for in vitro discovery and validation of new candidate mitogens affecting regenerative or maturation states of cardiomyocytes.
- 19 September 2024
- Published by Elsevier in Acta Biomaterialia
- Vol. 188, 65-78
Engineered myovascular tissues for studies of endothelial/satellite cell interactions
- 19 September 2024
- Published by Elsevier in Acta Biomaterialia
- Vol. 188, 65-78
Engineered myovascular tissues for studies of endothelial/satellite cell interactions
- Open Access
- 26 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (4) , eadh2598
Time-dependent effects of BRAF-V600E on cell cycling, metabolism, and function in engineered myocardium
Candidate cardiomyocyte (CM) mitogens such as those affecting the extracellular signal–regulated kinase (ERK) signaling pathway represent potential targets for functional heart regeneration. We explored whether activating ERK via a constitutively active mutant of B-raf proto-oncogene (BRAF), BRAF-V600E (caBRAF), can induce proproliferative effects in neonatal rat engineered cardiac tissues (ECTs). Sustained CM-specific caBRAF expression induced chronic ERK activation, substantial tissue growth, deficit in sarcomeres and contractile function, and tissue stiffening, all of which persisted for at least 4 weeks of culture. caBRAF-expressing CMs in ECTs exhibited broad transcriptomic changes, shift to glycolytic metabolism, loss of connexin-43, and a promigratory phenotype. Transient, doxycycline-controlled caBRAF expression revealed that the induction of CM cycling is rapid and precedes functional decline, and the effects are reversible only with short-lived ERK activation. Together, direct activation of the BRAF kinase is sufficient to modulate CM cycling and functional phenotype, offering mechanistic insights into roles of ERK signaling in the context of cardiac development and regeneration.
- 26 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (4) , eadh2598
Open AccessTime-dependent effects of BRAF-V600E on cell cycling, metabolism, and function in engineered myocardium
Candidate cardiomyocyte (CM) mitogens such as those affecting the extracellular signal–regulated kinase (ERK) signaling pathway represent potential targets for functional heart regeneration. We explored whether activating ERK via a constitutively active mutant of B-raf proto-oncogene (BRAF), BRAF-V600E (caBRAF), can induce proproliferative effects in neonatal rat engineered cardiac tissues (ECTs). Sustained CM-specific caBRAF expression induced chronic ERK activation, substantial tissue growth, deficit in sarcomeres and contractile function, and tissue stiffening, all of which persisted for at least 4 weeks of culture. caBRAF-expressing CMs in ECTs exhibited broad transcriptomic changes, shift to glycolytic metabolism, loss of connexin-43, and a promigratory phenotype. Transient, doxycycline-controlled caBRAF expression revealed that the induction of CM cycling is rapid and precedes functional decline, and the effects are reversible only with short-lived ERK activation. Together, direct activation of the BRAF kinase is sufficient to modulate CM cycling and functional phenotype, offering mechanistic insights into roles of ERK signaling in the context of cardiac development and regeneration.
- Open Access
- 16 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Author Correction: Engineered bacterial voltage-gated sodium channel platform for cardiac gene therapy
- 16 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Open AccessAuthor Correction: Engineered bacterial voltage-gated sodium channel platform for cardiac gene therapy
- Open Access
BRAF-V600E-Mediated Erk Activation Promotes Sustained Cell Cycling and Broad Transcriptional Changes in Neonatal Cardiomyocytes
Mitogens capable of promoting cardiomyocyte proliferation represent important targets for functional heart regeneration following myocardial infarction. We previously described an ERK-dependent pro-proliferative tissue phenotype following overexpression of constitutively-active (ca) human ERBB2 in both neonatal rat ventricular myocytes (NRVMs) and human iPSC-derived cardiomyocytes (hiPSC-CMs). Since ERBB2 canonically regulates multiple other pathways in addition to ERK, it is unclear whether ERK activation alone can drive CM proliferation. Here, we activated ERK in a targeted fashion by CM-specific lentiviral expression of a constitutively active mutant of BRAF, BRAF-V600E (caBRAF), in cultured NRVMs and examined the effects on engineered NRVM tissue proliferation, morphology, and function. caBRAF expression induced ERK activation, tissue growth, loss of contractile function, and increased tissue stiffness, all of which were sustained for at least 4 weeks in vitro . From bulk RNA-sequencing analysis of engineered tissues, we found that caBRAF had broad transcriptomic effects on CMs and induced a shift to glycolytic metabolism. Together, this work shows that direct ERK activation is sufficient to modulate CM cycling and functional maturation in a cell-autonomous fashion and could offer a potential target for cardiac regenerative therapies.
Open AccessBRAF-V600E-Mediated Erk Activation Promotes Sustained Cell Cycling and Broad Transcriptional Changes in Neonatal Cardiomyocytes
Mitogens capable of promoting cardiomyocyte proliferation represent important targets for functional heart regeneration following myocardial infarction. We previously described an ERK-dependent pro-proliferative tissue phenotype following overexpression of constitutively-active (ca) human ERBB2 in both neonatal rat ventricular myocytes (NRVMs) and human iPSC-derived cardiomyocytes (hiPSC-CMs). Since ERBB2 canonically regulates multiple other pathways in addition to ERK, it is unclear whether ERK activation alone can drive CM proliferation. Here, we activated ERK in a targeted fashion by CM-specific lentiviral expression of a constitutively active mutant of BRAF, BRAF-V600E (caBRAF), in cultured NRVMs and examined the effects on engineered NRVM tissue proliferation, morphology, and function. caBRAF expression induced ERK activation, tissue growth, loss of contractile function, and increased tissue stiffness, all of which were sustained for at least 4 weeks in vitro . From bulk RNA-sequencing analysis of engineered tissues, we found that caBRAF had broad transcriptomic effects on CMs and induced a shift to glycolytic metabolism. Together, this work shows that direct ERK activation is sufficient to modulate CM cycling and functional maturation in a cell-autonomous fashion and could offer a potential target for cardiac regenerative therapies.
- Open Access
- 2 February 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-17
Engineered bacterial voltage-gated sodium channel platform for cardiac gene therapy
Therapies for cardiac arrhythmias could greatly benefit from approaches to enhance electrical excitability and action potential conduction in the heart by stably overexpressing mammalian voltage-gated sodium channels. However, the large size of these channels precludes their incorporation into therapeutic viral vectors. Here, we report a platform utilizing small-size, codon-optimized engineered prokaryotic sodium channels (BacNav) driven by muscle-specific promoters that significantly enhance excitability and conduction in rat and human cardiomyocytes in vitro and adult cardiac tissues from multiple species in silico. We also show that the expression of BacNav significantly reduces occurrence of conduction block and reentrant arrhythmias in fibrotic cardiac cultures. Moreover, functional BacNav channels are stably expressed in healthy mouse hearts six weeks following intravenous injection of self-complementary adeno-associated virus (scAAV) without causing any adverse effects on cardiac electrophysiology. The large diversity of prokaryotic sodium channels and experimental-computational platform reported in this study should facilitate the development and evaluation of BacNav-based gene therapies for cardiac conduction disorders.
- 2 February 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-17
Open AccessEngineered bacterial voltage-gated sodium channel platform for cardiac gene therapy
Therapies for cardiac arrhythmias could greatly benefit from approaches to enhance electrical excitability and action potential conduction in the heart by stably overexpressing mammalian voltage-gated sodium channels. However, the large size of these channels precludes their incorporation into therapeutic viral vectors. Here, we report a platform utilizing small-size, codon-optimized engineered prokaryotic sodium channels (BacNav) driven by muscle-specific promoters that significantly enhance excitability and conduction in rat and human cardiomyocytes in vitro and adult cardiac tissues from multiple species in silico. We also show that the expression of BacNav significantly reduces occurrence of conduction block and reentrant arrhythmias in fibrotic cardiac cultures. Moreover, functional BacNav channels are stably expressed in healthy mouse hearts six weeks following intravenous injection of self-complementary adeno-associated virus (scAAV) without causing any adverse effects on cardiac electrophysiology. The large diversity of prokaryotic sodium channels and experimental-computational platform reported in this study should facilitate the development and evaluation of BacNav-based gene therapies for cardiac conduction disorders.
- Open Access
Human Erbb2-induced Erk Activity Robustly Stimulates Cycling and Functional Remodeling of Rat and Human Cardiomyocytes
Multiple mitogenic pathways capable of promoting mammalian cardiomyocyte (CM) proliferation have been identified as potential candidates for functional heart repair following myocardial infarction. However, it is unclear whether the effects of these mitogens are species-specific and how they directly compare in the same cardiac setting. Here, we examined how CM-specific lentiviral expression of various candidate mitogens affects human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and neonatal rat ventricular myocytes (NRVMs) in vitro . In 2D-cultured CMs from both species, and in highly mature 3D-engineered cardiac tissues generated from NRVMs, a constitutively-active mutant form of the human gene Erbb2 (cahErbb2) was the most potent tested mitogen. Persistent expression of cahErbb2 induced CM proliferation, sarcomere loss, and remodeling of tissue structure and function, which were attenuated by small molecule inhibitors of Erk signaling. These results suggest transient activation of Erbb2/Erk axis in cardiomyocytes as a potential strategy for regenerative heart repair.
Open AccessHuman Erbb2-induced Erk Activity Robustly Stimulates Cycling and Functional Remodeling of Rat and Human Cardiomyocytes
Multiple mitogenic pathways capable of promoting mammalian cardiomyocyte (CM) proliferation have been identified as potential candidates for functional heart repair following myocardial infarction. However, it is unclear whether the effects of these mitogens are species-specific and how they directly compare in the same cardiac setting. Here, we examined how CM-specific lentiviral expression of various candidate mitogens affects human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and neonatal rat ventricular myocytes (NRVMs) in vitro . In 2D-cultured CMs from both species, and in highly mature 3D-engineered cardiac tissues generated from NRVMs, a constitutively-active mutant form of the human gene Erbb2 (cahErbb2) was the most potent tested mitogen. Persistent expression of cahErbb2 induced CM proliferation, sarcomere loss, and remodeling of tissue structure and function, which were attenuated by small molecule inhibitors of Erk signaling. These results suggest transient activation of Erbb2/Erk axis in cardiomyocytes as a potential strategy for regenerative heart repair.